PROCEPT BioRobotics Corp

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in Redwood City, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PROCEPT BioRobotics Corp achieves record revenue growth, eyes market expansion

PROCEPT BioRobotics Corp demonstrated strong financial growth in Q4 2022, with revenue surging by 135% year-over-year, setting the stage for continued expansion and market success.
While facing challenges such as high operating expenses and margin pressures, the company remains focused on innovation, market diversification, and operational improvements to drive future profitability.
With a clear strategy to enhance sales efforts, expand market reach, and invest in R&D, PROCEPT BioRobotics Corp is well-positioned to capitalize on growth opportunities and solidify its presence in the medical technology sector.
Overall, the company's performance highlights a balance between revenue growth initiatives, cost management strategies, and a commitment to delivering high-quality healthcare solutions, signaling a positive outlook for future success.

PROCEPT BioRobotics Corp reports strong Q1 growth and eyes global expansion

PROCEPT BioRobotics Corp delivered strong Q1 results with robust revenue growth and margin expectations, despite profitability challenges.
The company's focus on long-term growth, pricing discipline, and market opportunities position it well for future success and becoming a standard of care for BPH.
While facing challenges like operating expenses and sales performance, PROCEPT BioRobotics remains optimistic about international expansion and market potential.
With a solid financial foundation, high surgeon retention rates, and exciting growth prospects in new markets, the company is poised for continued success.

PROCEPT BioRobotics Corp achieves record revenue and strategic partnerships

PROCEPT BioRobotics delivered a standout performance in Q2 2023, marked by record revenue, strong U.S. system sales, and international growth, supported by strategic partnerships and positive payer coverage updates.
While facing challenges from dilutive effects of new system placements and market evaluation complexities, the company's focus on innovation, financial strength, and growth opportunities position them well for future success.
By capitalizing on the momentum in system sales, expanding market reach, and leveraging the trend towards innovative treatments, PROCEPT BioRobotics is poised for continued growth and market leadership in the healthcare sector.

PROCEPT BioRobotics reports record Q3 revenue and eyes international expansion

PROCEPT BioRobotics delivered a strong quarter marked by revenue growth, improved gross margin, and strategic equity financing, positioning the company for future success.
While facing challenges in profitability and international sales, the company's focus on cost control, expansion, and innovative therapies presents avenues for growth and market leadership.
Overall, PRCT's performance reflects resilience and strategic foresight, supported by a confident management team and a clear vision for sustained growth and profitability.

PROCEPT BioRobotics Corp reports robust revenue growth and strategic focus

PROCEPT BioRobotics Corp delivered strong revenue growth in Q4 2023 and provided optimistic guidance for 2024, focusing on gross margin expansion and disciplined expense management.
The company's strategic strengths lie in innovation, customer base expansion, and patient awareness initiatives, while challenges include managing operating expenses and market dynamics.
Opportunities for PROCEPT include leveraging R&D investments, patient education, and market presentations to capture a larger share of the BPH patient population and drive utilization growth.
Overall, PROCEPT's performance highlights its commitment to long-term value creation, market stability, and strategic growth initiatives in the medical robotics sector.

PROCEPT BioRobotics Corp reports strong revenue growth and strategic advancements

PROCEPT BioRobotics Corp delivered strong revenue growth in Q1 2024, driven by robust U.S. sales and improved gross margins. The company's strategic focus on profitability, customer relationships, and product safety positions it well for future success.
While facing challenges with net losses and high operating expenses, PROCEPT BioRobotics Corp has opportunities to drive growth through ASC procedures, international expansion, and clinical trials. Leveraging strategic partnerships and market-leading products will be key to overcoming challenges and seizing opportunities.
Overall, PROCEPT BioRobotics Corp's Q1 performance reflects a mix of strengths, challenges, and opportunities. By navigating financial hurdles, capitalizing on market trends, and maintaining a customer-centric approach, the company can drive sustainable growth and enhance its competitive position.

PROCEPT BioRobotics reports strong revenue growth but faces profitability challenges

PROCEPT BioRobotics delivered robust revenue growth and margin expansion in Q2 2024, driven by strong U.S. sales and operational efficiency. However, escalating operating expenses led to a net loss and negative adjusted EBITDA.
The company's strategic focus on leveraging fixed costs and sustaining revenue growth presents opportunities for long-term profitability and market expansion. Balancing cost control with revenue generation will be crucial for future success.
Despite challenges in achieving profitability, PROCEPT BioRobotics remains confident in its ability to drive margin expansion through increased revenues and operational efficiencies, positioning itself for sustained growth and financial improvement.

PROCEPT BioRobotics excels in Q3 with revenue surge and innovation

PROCEPT BioRobotics delivered strong revenue growth, margin improvement, and operational progress in Q3 2024, underpinned by market acceptance and innovation.
While facing challenges in managing expenses and achieving profitability, the company's solid financial position and growth outlook offer opportunities for future success.
By focusing on cost optimization, product differentiation, and strategic investments, PROCEPT can navigate challenges and leverage opportunities to drive sustained growth and value creation.
Overall, PROCEPT's performance reflects resilience and potential for continued expansion in the robotic medical systems market, supported by a strong financial foundation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in San Jose, CA.

SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024

Cognex

Columbus McKinnon

Right now, growth investors are focused primarily on opportunities in the semiconductors and artificial intelligence stocks space. That's understandable, given how fast technology is advancing in those areas right now.

You've Been Warned! 3 Robotics Stocks to Buy Now or Regret Forever.

SAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association (“AMA”) has established a new Current Procedural Terminology (“CPT”) Category I code for transurethral waterjet resection of prostate tissue (“Aquablation therapy”) to treat benign prostatic hyperplasia (“BPH”).

PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy

SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time.

PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024

UiPath

Robotics stocks should be a leading investment theme throughout the 2020s. The concept of automating factories, warehouses and data entry work has long appealed to large corporations.

From Science Fiction to Reality: 3 Robotics Stocks for Automatic Riches

SAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20 a.m. Eastern Time. Additionally, members of management will present at the upcoming 44th Annual William Blair Growth Stock Conference in Chicago. Management is scheduled to present on Tuesday, June 4 at 5:00 p.m. Eastern Time.

PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference

Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy's potential to become the new standard of care in BPH for prostates of all sizes Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy's potential to become the new standard of care in BPH for prostates of all sizes

Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia

PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q1 2024 Earnings Conference Call May 1, 2024 9:00 AM ET Company Participants Matt Basco - Vice President, Investor Relations Reza Zadno - Chief Executive Officer Sham Shiblaq - Chief Commercial Officer Kevin Waters - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Matthew O'Brien - Piper Sandler Josh Jennings - TD Cowen Richard Newitter - Truist. Brandon Vasquez - William Blair Chris Pasquale - Nephron Research Nathan Treybeck - Wells Fargo Ryan Zimmerman - BTIG Mike Kratky - Leerink Partners Operator Good morning and welcome to PROCEPT BioRobotics First Quarter 2024 Earnings Conference Call.

PROCEPT BioRobotics Corporation (PRCT) Q1 2024 Earnings Call Transcript

Procept Stock: Biotech leader Procept BioRobotics is breaking out past its latest buy point. Shares jumped on Q1 earnings results Wednesday.

Biotech Leader Procept BioRobotics Jumps Past Buy Point On Earnings

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.63 per share a year ago.

PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates

SAN JOSE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2024.

PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

Presentations include first published experience report of same-day discharge in an ambulatory surgical center, real-world data outcomes and 5-year data comparison between two FDA trials Presentations include first published experience report of same-day discharge in an ambulatory surgical center, real-world data outcomes and 5-year data comparison between two FDA trials

PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting

SAN JOSE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, May 3, 2024, at the Grand Hyatt Hotel in San Antonio, TX at the American Urological Association Annual Meeting from 8:00am to 9:30am Central Time.

PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas

SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 1, 2024. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.

PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024

Ascendis Pharma

iShares U.S. Medical Devices ETF

SPDR S&P Health Care Equipment ETF

Procept BioRobotics and Ascendis Pharma may not show profits but the stocks have outperformed the S&P 500 in 2024. Shares are near buy points.

Two Health Care Stocks Outperform S&P 500, Offer Entries

Bio stock leader Procept BioRobotics is within striking distance of a new buy trigger after reporting earnings late Tuesday.

Bio Stock Procept BioRobotics Eyes Rare Buy Trigger After Earnings

PROCEPT BioRobotics Corporation (PRCT) Q4 2023 Earnings Call Transcript

SAN JOSE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2023.

PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results

PROCEPT BioRobotics Corporation (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Should You Buy?

Glaukos

Globus Medical

Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.

3 Medtech Stocks Likely to Top Estimates This Earnings Season

SAN JOSE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 44th Annual TD Cowen Health Care Conference in Boston. Management is scheduled to present on Tuesday, March 5 at 12:50 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston

PROCEPT BioRobotics Corporation (PRCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in PROCEPT BioRobotics Corporation (PRCT): Can Its 15.1% Jump Turn into More Strength?

SAN JOSE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported preliminary unaudited revenue for the quarter and fiscal year ended December 31, 2023.

PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million

SAN JOSE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 35th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, November 29 at 1:30 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City

The mean of analysts' price targets for PROCEPT BioRobotics Corporation (PRCT) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

News for PROCEPT BioRobotics Corp Stock (PRCT)